

Taldefgrobep alfa

Cat. No.:	HY-P99518
CAS No.:	1580555-26-5
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Taldefgrobep alfa (BMS 986089; RG 6206; RO 7239361) is a potent inhibitory antibody targeting to human myostatin. Taldefgrobep alfa is a fusion protein composed of a human IgG1-Fc domain and Adnectin domain. Taldefgrobep alfa can be used for spinal muscular atrophy (SMA) research ^{[1][2]} .
IC ₅₀ & Target	Myostatin ^[1]
In Vivo	Taldefgrobep alfa (2 mg/kg; iv or sc; single dose) has rapid plasma clearance after intravenous administration in mice, but slow absorption (T _{max} =24 h) after subcutaneous administration with C _{max} =15.4 mg/mL and bioavailability (F)=84% ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Zhu Y, et al. LC-MS/MS multiplexed assay for the quantitation of a therapeutic protein BMS-986089 and the target protein Myostatin. *Bioanalysis*. 2016 Feb;8(3):193-204.
- [2]. Straus M. 2023 Pipeline Report: Testing the Limits[J]. *Pharmaceutical Executive*, 2022, 42(12).

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA